Shares of Opko Health Inc. (NYSE:OPK) ended Monday session in green amid volatile trading. The shares closed up +0.18 points or 1.99% at $9.23 with 4.24 million shares getting traded. Post opening the session at $9.06, the shares hit an intraday low of $9.04 and an intraday high of $9.41 and the price vacillated in this range throughout the day. The company has a market cap of $4.94 billion and the numbers of outstanding shares have been calculated to be 547.44 million shares.
Opko Health Inc. (OPK) on June 13, 2016 announcesd that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the “NYSE”). The Company expects its common stock will begin trading on the NASDAQ Global Select Market (“NASDAQ”) on June 24, 2016, and its shares will continue to trade under the ticker symbol “OPK.”
“NASDAQ is home to many of the world’s best healthcare companies and is a natural fit for OPKO. This move will enhance our public visibility while offering our stockholders cost effective access to advanced trading technologies,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.
Bob Greifeld, CEO of Nasdaq, said, “Under the leadership of Dr. Frost, OPKO has long been recognized for driving innovation in the pharmaceutical and diagnostics industries to create products that improve our lives. We are proud to welcome the company to Nasdaq.”
The Company has notified the NYSE that it will voluntarily delist its common stock from the NYSE. The last day of trading of the common stock on the NYSE is expected to be on or about June 23, 2016. Until the Company’s Common Stock begins trading on NASDAQ, the Company’s Common Stock will remain trading on NYSE under the ticker symbol “OPK.”
Shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) ended Monday session in red amid volatile trading. The shares closed down -0.036 points or -7.38% at $0.449 with 4.20 million shares getting traded. Post opening the session at $0.47, the shares hit an intraday low of $0.44 and an intraday high of $0.50 and the price vacillated in this range throughout the day. The company has a market cap of $24.65 million and the numbers of outstanding shares have been calculated to be 61.13 million shares.
Pernix Therapeutics Holdings Inc (PTX) on May 25, 2016 announced that the United States Patent and Trademark Office has issued U.S. Patent Numbers 9,339,499 (‘499 patent), 9,326,982 (‘982 patent), and 9,333,201 (‘201 patent), covering important safety information related to dosing patients with Zohydro ER with BeadTek. These patents, in addition to the 9,265,760 patent (‘760 patent) which issued February 23, 2016, are broadly directed to a method of dosing patients with hepatic impairment with hydrocodone where no adjustment in start dose is needed for patients with mild or moderate hepatic impairment. The ‘760, ‘499, ‘982 and ‘201 patents expire July 25, 2033.
“The ‘499, ‘982, and the ‘201 patents, solely owned by Pernix, are a significant addition to the Orange Book, bringing the total number of Orange Book listed patents covering Zohydro ER with BeadTek to seven,” said John Sedor, Chairman and Interim CEO of Pernix Therapeutics. “We continue to invest in this brand and currently have a half dozen more patent applications pending relating to Zohydro ER with BeadTek.”